IRulya Therapeutics Inc.
IRLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by IRulya Therapeutics Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q3 2026, worth $66.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:25 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Mar 24, 2025 | – | Jan 30, 2023 | Feb 2, 2022 |
| Operating expenses | $58.1M | $57.3M | $34.6M | $52.0M | $90.3M |
| Research and development | $35.4M | $18.6M | $9.45M | $25.2M | $60.8M |
| Selling, general and administrative | $15.0M | $17.6M | $17.7M | $26.0M | $29.5M |
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M |
| Income tax | $3.21M | $87.0K | $197.0K | -$284.0K | – |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M | -$89.9M |
| EPS, basic | $-1.68 | $-1.31 | $-0.84 | $-1.54 | – |
| EPS, diluted | $-1.68 | $-1.31 | $-0.84 | $-1.54 | – |
| Weighted shares, basic | 50.1M | 43.3M | 37.2M | 33.5M | – |
| Weighted shares, diluted | 50.1M | 43.3M | 37.2M | 33.5M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Mar 24, 2025 | – | Jan 30, 2023 | Feb 2, 2022 |
| Cash and equivalents | $5.81M | – | – | – | – |
| Total current assets | $22.9M | $44.0M | $77.4M | $93.7M | $111.7M |
| Property, plant and equipment | $595.0K | $315.0K | $234.0K | $393.0K | $263.0K |
| Goodwill | – | $0 | $17.6M | $0 | – |
| Intangible assets | $67.8M | $60.0M | $63.7M | $5.90M | – |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M |
| Accounts payable | $2.22M | $2.90M | $2.03M | $570.0K | $4.91M |
| Short-term debt | $18.0M | – | – | – | – |
| Total current liabilities | $43.2M | $7.28M | $9.57M | $3.07M | $14.2M |
| Long-term debt | $0 | $14.3M | $13.4M | – | – |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.32M | $14.6M |
| Shareholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M | $118.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Mar 24, 2025 | – | Jan 30, 2023 | Feb 2, 2022 |
| Operating cash flow | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M |
| Capital expenditures | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M |
| Depreciation and amortization | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K |
| Stock-based compensation | $5.11M | $4.75M | $5.22M | $16.6M | $29.9M |
| Investing cash flow | $23.2M | $21.9M | -$5.76M | $18.0M | $59.0M |
| Financing cash flow | $17.9M | -$4.78M | $143.0K | $707.0K | $6.81M |
| Net change in cash | -$403.0K | -$14.5M | -$23.8M | -$25.1M | $2.88M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10.8M | −80.5% | SEC |
| Aug 7, 2026 | 1.02M | −98.1% | SEC |
| May 4, 2026 | 16.3M | −64.1% | SEC |
| Apr 9, 2026 | 163.0M | +258.5% | SEC |
| Nov 6, 2025 | 55.7M | +26.5% | SEC |
| Aug 5, 2025 | 53.7M | +24.1% | SEC |
| May 6, 2025 | 45.5M | +5.2% | SEC |
| Mar 13, 2025 | 44.0M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.